Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
31 juil. 2024 07h30 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 12th annual Regeneron Prize for Creative Innovation (the...
BioNTech gibt erste positive Ergebnisse aus laufender Phase-2-Studie mit mRNA-basiertem Immuntherapiekandidaten BNT111 bei fortgeschrittenem Hautkrebs bekannt
30 juil. 2024 06h45 HE
|
BioNTech SE
Primärer Endpunkt in Phase-2-Studie erreicht, in der der mRNA-Immuntherapiekandidat BNT111 in Kombination mit dem PD-1-Checkpoint-Inhibitor Cemiplimab evaluiert wirdDaten zeigten eine statistisch...
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
30 juil. 2024 06h45 HE
|
BioNTech SE
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically...
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
18 juil. 2024 10h05 HE
|
Spherix Global Insights
EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
24 juin 2024 09h27 HE
|
Spherix Global Insights
EXTON, PA., June 20, 2024, June 24, 2024 (GLOBE NEWSWIRE) -- The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly...
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
19 mai 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zymeworks Inc. (NASDAQ:...
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
17 mai 2024 13h45 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and WASHINGTON, D.C., May 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of...
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
17 avr. 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Regeneron...
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
11 avr. 2024 13h15 HE
|
Schall Law
The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
22 mars 2024 13h20 HE
|
KUEHN LAW, PLLC
Kuehn Law investigates potential breach of fiduciary duties by Regeneron Pharmaceuticals officers and directors. Shareholders urged to contact for details.